



**AAPM 2014**  
innovation

innovation

56<sup>th</sup> Annual Meeting & Exhibition • July 20–24, 2014 • Austin, TX

## Innovations in Clinical Breast Imaging

# Dedicated breast CT

**Kai Yang, Ph.D. DABR**

Department of Radiological Sciences

University of Oklahoma Health Sciences Center

[kai-yang@ouhsc.edu](mailto:kai-yang@ouhsc.edu)



The UNIVERSITY of OKLAHOMA  
Health Sciences Center

**UC DAVIS**

University of California, Davis

# Contributors

- John M. Boone, Ph.D., University of California, Davis.
- Srinivasan Vedantham, Ph.D., UMass Medical School.
- Peymon Gazi, M.S., University of California, Davis.

# Disclaimer

- Mention of any company or product does not constitute as endorsement.
- Dedicated breast CT has not been U.S. FDA approved for clinical use.

# Learning objectives

To understand the following topics after this talk:

- Rationale for dedicated breast CT
- Current development and clinical studies of breast CT
- Challenges for dedicated breast CT
- Considerations on quality assurance

# Breast CT (bCT)



**Introduction**



**Development of bCT**

**Patient imaging / clinical studies**

**Challenges for bCT**

**Quality assurance for bCT**

**Summary**



# Breast cancer facts and figures

About 40,000 deaths from breast cancer in 2011.

About 288,000 women diagnosed with breast cancer in 2011.

12.2% of women will get breast cancer sometime during their lifetime.

**Table 1. Estimated New Female Breast Cancer Cases and Deaths by Age, US, 2011\***

Age	In Situ Cases	Invasive Cases	Deaths
Under 40	1,780	11,330	1,160
Under 50	14,240	50,430	5,240
50-64	23,360	81,970	11,620
65+	20,050	98,080	22,660
<b>All ages</b>	<b>57,650</b>	<b>230,480</b>	<b>39,520</b>

\*Rounded to the nearest 10.

**Source:** Total estimated cases are based on 1995-2007 incidence rates from 46 states as reported by the North American Association for Central Cancer Registries. Total estimated deaths are based on data from US Mortality Data, 1969-2007, National Center for Health Statistics, Centers for Disease Control and Prevention.

American Cancer Society, Surveillance Research, 2011

**Table 5. Age-specific Probabilities of Developing Invasive Female Breast Cancer\***


If current age is ...	The probability of developing breast cancer in the next 10 years is:	or 1 in:
20	0.06%	1,681
30	0.43%	232
40	1.45%	69
50	2.38%	42
60	3.45%	29
70	3.74%	27
<b>Lifetime risk</b>	<b>12.15%</b>	<b>8</b>

\*Among those free of cancer at beginning of age interval. Based on cases diagnosed 2005-2007. Percentages and "1 in" numbers may not be numerically equivalent due to rounding.

Probability derived using NCI DevCan Software, Version 6.5.0.


American Cancer Society, Surveillance Research, 2011

# Mammography: standard of care





# Cancer prognosis and screening

Age-Adjusted Cancer Death Rates,\* Females by Site, US, 1930-2004




# Major limitation of mammography

## Tissue overlapping – “Anatomical noise” especially for dense breasts




**Breast density in the U.S.** (See pie chart)

- 10% of women have almost entirely fatty breasts
- 10% have extremely dense breasts
- 80% are classified into one of two middle categories



<http://www.breastdensity.info>

# Breast density notification/reporting law



**PINK: Enacted Law**  
**RED: Introduced Bill**  
**BLUE: Working on Bill**  
**WHITE: No Action**  
**BLACK : Insurance Coverage Law**


<http://www.areyoudenseadvocacy.org/>

*"If you have dense breast tissue, the odds of finding a cancer on your mammogram are about equal to a coin toss."*

Dr. Stacey Vitiello

# Rationale for a tomographic modality

## 2D vs. 3D






Background Noise

Anatomical Noise

low




high



**Digital Subtraction  
Angiography  
(Temporal Subtraction)**

**Reduces Anatomical Noise**




**Dual Energy Chest  
Radiography  
(Energy Subtraction)**

**Reduces Anatomical Noise**





# Rationale for a tomographic modality

## Mammography



$70\ \mu\text{m} \times 70\ \mu\text{m} \times 50,000\ \mu\text{m} \quad \sim 0.25\ \text{mm}^3$

## Breast CT (bCT)



$\sim 0.013\ \text{mm}^3$

$230\ \mu\text{m} \times 230\ \mu\text{m} \times 250\ \mu\text{m}^{14}$

# Breast CT (bCT)

## Introduction


➔ Development of bCT

Patient imaging / clinical studies

Challenges for bCT

Quality assurance for bCT


Summary



# Dedicated breast CT - Timeline

## 1970's-80's

Chang et al., Univ. of Kansas Med Ctr.



127 Xe detectors  
1.56 x 1.56 x 10 mm  
127 x 127 reconstruction  
CT #: -127 to 128 HU


1625 patients (78 cancers)  
IV contrast media  
94% detection rate vs.  
77% for mammography

Chang et al., Cancer 46:939-946, 1980.  
© American Cancer Society

## 2000 onwards

Boone et al., Radiology 221: 657-67, 2001.


Reported on glandular dose estimates  
with dedicated breast CT



Boone et al., Radiology 221: 657-67, 2001  
© 2001 Radiological Society of North America

# Dedicated breast CT- an ongoing research

- UC Davis



- U Mass Worcester

- U Nurnberg

- U Rochester



- MD Anderson

- Duke



- Louisiana State University

- Universita di Napoli




- Universita di Bologna

- UC Irvine



# Current clinical breast CT imaging

- Tungsten anode x-ray tube
- Cone beam geometry with flat panel detectors (CsI:Tl + a:Si)
- 10~20 seconds scanning time
- 300~512 images across the breast in 360 degrees
- FDK or iterative reconstruction
- Prone patient position
- Breast pendant through a hole
- No compression
- Equal radiation dose to 2-view mammography



# BCT Specs – Representative Systems

Parameter	UC Davis (Doheny)	Koning Standard(UMass†)	Duke/Zumat ek
X-ray tube	Varian M-1500	Varian Rad 71SP(M-1500)	Varian (Rad 94)
Focal spot (mm)	0.3	0.1/0.3 (0.3)	0.4
kVp/Filtration	60 kVp / Cu	49-60 kVp / Al	65 kVp / Ce
1 <sup>st</sup> HVL (mm of Al)	~4.15	~1.4@49 kV	~3.0
X-ray pulsing	Pulsed (3~8 ms)	Pulsed (8 ms)	Pulsed (25 ms)
No. of projections	500~800	300	300
Magnification factor	1.39	1.42	1.63
Detector	Dexela 2923M	Varian PaxScan 4030 CB (4030 MCT‡)	Varian PaxScan 2520
Detector type	CMOS+ CsI:Tl	a-Si + CsI:Tl	a-Si + CsI:Tl
Detector‡ pixel size/FPS	75 $\mu\text{m}$ x 2 / 50	194 $\mu\text{m}$ x 2 / 30	127 $\mu\text{m}$ x 2 / 5
Reconstruction / voxel (mm)	FBP / 110-200	FBP / 155 or 273	OSTR / 254 or 508

† Built to specific request by UMass

‡ Reduced dead-space at chest-wall

Slide contents courtesy: Srinivasan Vedantham, Ph.D., UMass

# Breast CT (bCT)

Introduction


Development of bCT

➔ Patient imaging / clinical studies

Challenges for bCT

Quality assurance for bCT

Summary



# Ongoing clinical studies (Partial list)

## Locations:


- Univ. of California, Davis
- Univ. of Pittsburgh Medical Center
- Univ. of Rochester Medical Center
- UMass Medical School
- M.D. Anderson Cancer Center
- Medical University of South Carolina
- Duke University
- Emory University
- Elizabeth Wende Breast Care

## Studies:

- Non-contrast breast CT
- Contrast-enhanced breast CT
- Dedicated breast CT with PET
- Dedicated breast CT with SPECT



# BCT (without injected contrast)




# BCT (without injected contrast)

Pre-pectoral  
Saline  
Implants


Diagnosis:  
IDC/ILC

UC Davis  
January 2005





# Breast CT clinical studies

Radiologist Subjective Scoring (N = 69)




K.K. Lindfors, et al. Radiology 246.3 (2008): 725.


# BCT (with contrast injection)



# Contrast Enhanced bCT DCIS





**Coronal**




**Sagittal**

**Rt ML Mag view**




**Axial**

# Breast CT clinical studies



## Contrast Agent Kinetics




Malignant tumors tend to enhance more than benign lesions


N. D. Prionas, et al Radiology 256, 714-723 (2010).

# Breast CT clinical studies


## Comparison between modalities



## Mammo vs. Tomo vs. CE-bCT




**Mammograms  
Apr 2010:  
Normal**



**Mammograms  
July 2011:  
DCIS**

**2011: DCE MRI  
showing  
enhancement**

**2010: CE bCT  
showing  
enhancement**



# Breast CT (bCT)

Introduction


Development of bCT

Patient imaging / clinical studies

➔ Challenges for bCT

Quality assurance for bCT

Summary



# Demands on breast CT imaging

1. Full 3D capability
2. Good soft-tissue differentiation
3. Dynamic imaging capabilities
4. High isotropic spatial resolution of about 100  $\mu\text{m}$
5. Low patient dose with an AGD below 5 mGy
6. Patient comfort without breast compression
7. Low cost

*Computed Tomography: Fundamentals, System Technology, Image Quality, Applications, 3<sup>rd</sup> Edition. Willi A. Kalender*

# Limitations for breast CT imaging

<b>Radiation dose to the breast</b>	<b>Equal or less than two-view mammo</b>
<b>Patient's comfort</b>	<b>No breast compression Breath hold &lt; 20 seconds Natural prone position</b>
<b>Available technology and the cost</b>	<b>Indirect flat panel detector (a-Si TFT or CMOS) Pulsed x-ray tube</b>

# Challenges for bCT

## Mass-lesion detection

Soft tissue differentiation  
Quantitative information  
Contrast kinetics

## Micro-calcification detection



Spectrum optimization

Improve the spatial resolution

Improve the image SNR

Improve the accuracy of HU

## Chest wall coverage

Patient comfort



Table top/gantry design




# Challenges for bCT – Spectrum

Dose-normalized CNR  
(CNRD)

Iodine contrast:

Calcification contrast:

**60 kVp + 0.2 mm Cu**



# Challenges for bCT – $\mu$ Calcs detection

## Spatial resolution

Flat panel detector – frame rate, MTF, DQE

X-ray tube – focal spot, pulsed vs. continuous

## Contrast resolution

Relatively high kV (49~80 kV vs. 20~30 kV in mammo).


Potentially low contrast for calcifications.

Noise due to dose limit

To match the mean glandular dose of two-view mammo.

Potentially low SNR in each projection image.

# Challenges for bCT – $\mu$ Calcs detection



## Spatial Resolution

	Breast CT	Mammography
Detector pixel size (mm)	388 (150*)	75~100
X-ray focal spot size (mm)	0.1~0.4	0.1~0.4
Magnification factor	1.5~2.0	1.0~2.0

\* The "Doheny" scanner at UC Davis with a DEXELA CMOS detector.

# UD Davis bCT MTF - system improvement

Albion  
Bodega



1.0 mm focal spot  
Continuous acquisition



$388 \times 388 \mu\text{m}^2$   
30 fps

Cambria



0.3 mm focal spot  
Pulsed acquisition



$388 \times 388 \mu\text{m}^2$   
30 fps

Doheny







0.3 mm focal spot  
Pulsed acquisition



$150 \times 150 \mu\text{m}^2$   
60 fps

# UD Davis bCT MTF - system improvement





# Challenges for bCT - $\mu$ Calcs detection


## Radiation Dose vs. Noise

TABLE V. The minimum detectable MC sizes for various conditions for the small and the large breast phantoms.


Threshold	Breast phantom	MGD	X-ray tube voltage		
			60 kVp	8 kVp	100 kVp
50%	Small	3 mGy	346	349	—
		6 mGy	282	280	301
		12 mGy	253	258	259
	Large	6 mGy	357	353	354
		12 mGy	296	304	320
		24 mGy	—	270	279
75%	Small	3 mGy	368	366	—
		6 mGy	311	308	329
		12 mGy	261	264	271
	Large	6 mGy	382	373	376
		12 mGy	325	333	343
		24 mGy	—	298	301



14 cm diameter  $f_g = 0.15$  breast-equivalent phantom; Calcifications located at  $r = 3.5$  cm.



FBP: 273 microns  
Modified Shepp-Logan




FBP: 155 microns  
Ramp filter

Can visualize 220  $\mu\text{m}$  calcifications @ AGD  
matched to **diagnostic** mammography (12 mGy)


# Challenges for bCT – $\mu$ Calcs detection

BCT Denoise – Projection domain (PDEtomo)

without denoise




with denoise




# Challenges for bCT – $\mu$ Calcs detection

BCT Denoise – Projection domain (PDEtomo)

without denoise



with denoise





# Challenges for bCT – $\mu$ Calcs detection

BCT Denoise – CT image domain (iterative reconstruction).



FDK

ASD-POCS



FDK

ASD-POCS





# Challenges for bCT – $\mu$ Calcs detection




BCT Denoise – CT image domain (iterative reconstruction).

**FDK**

**PICCS**



# Challenges for bCT – Scatter



# Scatter correction approaches (Partial list)





- CT image processing based
  - Kachelriess et al. Medical Physics 33, 1269-1274 (2006).
  - Altunbas et al. Medical Physics 34, 3109-18 (2007).
- Monte Carlo simulation based
  - Gao et al. Medical Physics 37, 227-36 (2010).

**The absolute accuracy of HU is equally important as the image uniformity!**

- Ning et al. Medical Physics 31, 1195-202 (2004).
- X. Tang, United States Patent No. US 6876718B2 (2005).
- Siewerdsen et al. Medical Physics 33, 187-97 (2006).
- Maltz et al. Medical Physics 35, 2452-62 (2008).
- Jin et al. Medical Physics 37, 5634-44 (2010).
- Niu et al. Medical Physics 38, 6027-38 (2011).
- I. Sechopoulos, Medical Physics 39, 2896 (2012).

# Scatter Correction – The BPA Approach

$$\frac{(P+S) - P}{P} = \text{SPR}$$











SPR defined at various points


SPR Interpolated to entire image

# Scatter Correction – Cupping Correction

with scatter    after scatter correction    difference image



# Scatter Correction – HU Accuracy



# Challenges for bCT – Chest wall


Tabletop design

Patient comfort level



Physical limitations

Focal spot location

Detector dead space




# Challenges for bCT – Chest wall





# Improving chest wall coverage

## Dedicated breast CT: geometric design considerations to maximize posterior breast coverage

Srinivasan Vedantham, Andrew Karellas, Margaret M Emmons, Lawrence J Moss, Sarwat Hussain and Stephen P Baker



If using ideal tube/detector – breast CT would miss at the most 9 mm compared to mammography in 95% of women studied



Optimal swale depth,  $s_d^*$  depends on x-ray tube/detector dead-space and magnification [B - corresponds to the geometry with UMass prototype (3.2 cm)]

# Breast CT (bCT)

Introduction


Development of bCT

Patient imaging / clinical studies




Challenges for bCT

➔ Quality assurance for bCT

Summary



# Quality assurance for bCT



## A combination of CT and Mammo?

# Quality assurance for bCT

## Mammo Style

- Mechanical stability and safety
- kV accuracy, filtration and tube output linearity
- Focal spot size
- Collimation and field coverage
- Detector uniformity and lag

## CT Style


- Geometrical calibration (spatial accuracy)
- Image quality – MTF and NPS
- HU accuracy **One consolidated phantom?**
- Cone beam artifact
- Chest wall coverage

## CT + Mammo

- Radiation dose
- Image quality –  $\mu$ Calcs, mass **ACR phantom?**



# BCT QA – Radiation Dose

- Metric: Average Glandular Dose (AGD)
- Measure of radiation dose to “at-risk” glandular tissue
- Facilitates direct comparison with mammography
- Method:
  - Measure air kerma (mGy) at axis of rotation (AOR) without object (e.g., dosimetry phantom) over entire scan
  - Multiply by Monte Carlo-derived conversion factor ( $D_g N^{CT}$ ) in units of (mGy/mGy)



# BCT QA – Radiation Dose



radiation dose is size dependent!



$\bar{X} = 13.4$  cm  
 $\sigma = 2.0$  cm  
Median = 13.6 cm


2008 assessment on bCT images (N = 137)

2001 tape measure results (N = 200)




# BCT QA – Radiation Dose


## Monte Carlo Assessment of Dose Deposition



breast modeled as a cylinder




monoenergetic functions




# Mean Glandular Dose in Breast CT

## spectral model\*




\*The TASMIP model, JM Boone and JA Seibert, Medical Physics 24;1661-670, 1997.

## polyenergetic functions



# Breast CT technique chart




mA setting on Cambria			
Breast Diameter (cm)	0% Gland	50% Gland	1.00 Gland
10.0	37	51	72
10.5	48	67	95
11.0	59	82	117
11.5	72	100	143
12.0	87	123	175
12.5	106	150	214
13.0	130	184	263
13.5	157	224	322
14.0	189	271	389
14.5	224	323	465
15.0	262	379	548
15.5	301	437	633
16.0	340	495	719
16.5	377	550	800
17.0	409	598	872
17.5	433	636	929
18.0	447	658	964

*Dose in breast CT is set to be **EQUAL** to the dose of two-view mammography for that women.*


# BCT Radiation dose: diagnostic studies

Personalized estimates of radiation dose from dedicated breast CT in a diagnostic population and comparison with diagnostic mammography

Srinivasan Vedantham<sup>1,4</sup>, Linxi Shi<sup>1</sup>, Andrew Karellas<sup>1</sup>,  
Avice M O'Connell<sup>2</sup> and David L Conover<sup>3</sup>












Median of MGD from diagnostic breast CT is similar to diagnostic mammography with smaller range.



Median MGD from diagnostic breast CT is equivalent to 4-5 mammography views. Mean number of diagnostic mammography views in study: 4.53

# BCT QA – Image Quality



# Breast CT (bCT)

Introduction


Development of bCT

Patient imaging / clinical studies

Challenges for bCT

Quality assurance for bCT

➔ Summary



# Summary

- BCT can be performed in a dose efficient manner
- BCT almost certainly outperforms mammo for masses
- BCT might be possible for screening / need CALCS
- Needs to solve the challenges:
  - Resolution, SNR, Micro-Calcification, HU accuracy, and Chest wall
- BCT QA is a combination of CT and Mammo.

## Question #1:

Compared to mammography, current available clinical data showed that dedicated bCT\_\_\_\_\_

20% 1. takes shorter time for the exam.

20% 2. requires same amount of compression.

20% 3. has a better coverage of the chest wall.

20% 4. can detect micro-calcifications better.

20% 5. can detect mass-lesions better.

## Question #1:

Compared to mammography, current available clinical data showed that dedicated bCT \_\_\_\_\_.

1. takes shorter time for the exam.
2. requires same amount of breast compression.
3. has a better coverage of the chest wall.
4. can detect micro-calcifications better.
5. can detect mass-lesions better.

**Answer:** 5. can detect mass-lesions better.

Reference: K.K. Lindfors, et al. Radiology 246.3 (2008) 725.

## Question #2:

From one study mentioned in this talk, which of the following spectrum provides the highest dose-normalized CNR (CNRD) for bCT?

20% 1. 40 kV + 1.5 mm Al

20% 2. 60 kV + 1.5 mm Al

20% 3. 60 kV + 0.2 mm Cu

20% 4. 60 kV + 0.2 mm Sn

20% 5. 80 kV + 0.2 mm Cu

## Question #2:

From one study mentioned in this talk, which of the following spectrum provides the highest dose-normalized CNR (CNRD) for bCT?

1. 40 kV + 1.5 mm Al
2. 60 kV + 1.5 mm Al
3. 60 kV + 0.2 mm Cu
4. 60 kV + 0.2 mm Sn
5. 80 kV + 0.2 mm Cu

**Answer:** 3. 60 kV + 0.2 mm Cu

Reference: N.D. Prionas, et al, Med. Phys. 38, 646 (2011)

## Question #3:

As described in this talk, the radiation dose to the breast from a dedicated bCT scan is \_\_\_\_\_.

20%1. not related to the detection of micro-calcs.

20%2. independent to the size & density of the breast.

20%3. determined by the CTDI with a phantom.

20%4. proportional to the air kerma at isocenter.

20%5. unable to match mammographic procedures.

## Question #3:

As described in this talk, the radiation dose to the breast from a dedicated bCT scan is \_\_\_\_\_.

1. not related to the detection of micro-calcs.
2. independent to the size & density of the breast.
3. determined by the CTDI with a phantom.
4. proportional to the air kerma at isocenter.
5. unable to match mammographic procedures.

**Answer:** 4. proportional to the air kerma at isocenter.

**Reference:** Boone, J. M. et al Med. Phys. 32, 3767 (2005)

# Acknowledgement

This work was supported by grants from the California Breast Cancer Research Program (Grant Nos. 7EB-0075 and 11 IB-0114), the National Cancer Institute (Grant No. CA-89260), the National Institute for Biomedical Imaging and Bioengineering (Grant No. EBoo2138-03), and the Susan G. Komen Foundation.



# Acknowledgement



John Boone    Karen Lindfors    Tony Seibert    Ramsey Badawi    Simon Cherry    Shadi Shakeri    Tom Nelson    Craig Abbey    John Bishop    Yanhong Zhang    Richard Bold    Steve Martinez



Norbert Pelc    Elizabeth Krupinski    Bruce Hasegawa    Martin Yaffe    Jeff Siewerdsen    Loren Niklason    Carey Floyd    Maryellen Giger    Xiaochuan Pan    Jessie Xia    Junguo Bian    Ingrid Reiser    Alex Kwan    Hong Zhou



Whit Miller    Kai Yang    Orlando Velazquez    Clare Huang    Nathan Packard    Katie Metheany    Dandan Zheng    Shonket Ray    Anita Nosratieh    Lin Chen    Sarah McKenny    Nicolas Prionas    Peymon Gazi

Varian Imaging Systems



Larry Partain  
Gary Vishup  
John Pavkovich  
Hussan Mostafavi  
Gerhard Roos  
Ed Seppi  
Cesar Proano



Linda Phelps    Laurie Boling    George Burkett    Desiree Lazo    Fareedah Simon    John Brock

● deceased